Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
Portfolio Pulse from Vandana Singh
Genmab A/S (NASDAQ:GMAB) and AbbVie Inc (NYSE:ABBV) have announced positive topline results from the follicular lymphoma cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab. The study showed an overall response rate of 82%, exceeding the protocol-prespecified threshold for efficacy. The companies will engage with global regulatory authorities to determine the next steps.
June 28, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's stock could see a positive impact due to the positive results from the clinical trial of epcoritamab.
Positive clinical trial results often lead to increased investor confidence and can drive the stock price up. Given that AbbVie is one of the companies behind the trial, it is likely to see a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Genmab's stock could see a positive impact due to the positive results from the clinical trial of epcoritamab.
Positive clinical trial results often lead to increased investor confidence and can drive the stock price up. Given that Genmab is one of the companies behind the trial, it is likely to see a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50